Original ContributionHER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma*,**
References (23)
- et al.
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
Gastroenterology
(1993) - et al.
Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis
Eur J Surg Oncol
(1997) - et al.
The increasing frequency of adenocarcinoma of the esophagus
Cancer
(1989) - et al.
Continuing climb in rates of esophageal adenocarcinoma: An update
JAMA
(1993) - et al.
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Cancer
(1998) - et al.
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
Cancer Res
(1988) - et al.
Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases
Mod Pathol
(1991) - et al.
Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease
Cancer Res
(1993) - et al.
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group
J Clin Oncol
(1993) - et al.
Oncogenes and oncosuppressor gene in adeonocarcinoma of the oesophagus
Gut
(1992)
Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas
Int J Cancer
(1993)
Cited by (133)
Management of Locally Advanced Esophageal Cancer
2020, Surgical Oncology Clinics of North AmericaCancer of the Esophagus
2019, Abeloff’s Clinical OncologyHER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study
2016, European Journal of Surgical OncologyBrain Metastases from Esophageal Cancer in the Presence of HER-2 Overexpression
2015, Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy
- *
Supported in part by funds from a Pathology Applications Grant from Ventana Medical Systems. Dr. Ross serves as Medical Director of Ventana Medical Systems.
- **
Presented in part at the 88th Annual Meeting of the United States and Canadian Academy of Pathology, San Francisco, CA, March 1999.
Copyright © 2000 Published by Elsevier Inc.